Colorectal cancer is the third-most-common cancer globally and is associated with a five-year OS of Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in combination with angiogenesis inhibitors and EGFR inhibitors. Several areas of high unmet need—notably, treatments for the adjuvant and first-line patient populations—offer significant commercial opportunity for innovative agents. Several immune checkpoint inhibitors are in early- and late-phase development across lines of therapy and have the potential to significantly alter the treatment paradigm. This report provides insight on how treatment options for colorectal cancer are likely to change over the 2015-2025 forecast period. It also analyzes the current and future earnings potential of drugs already in the market and those expected to be approved for colorectal cancer.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 21 country-specific interviews with thought leaders.
Epidemiology: diagnosed incident cases of stage I, II, III , and IV colorectal cancer.
Population segments in market forecast :
Colon cancer stage II, rectal cancer stage II, colon cancer stage III, rectal cancer stage III, stage IV colorectal cancer wild-type RAS, first-line, stage IV colorectal cancer mutant RAS, first-line, stage IV colorectal cancer wild-type RAS, second-line, stage IV colorectal cancer mutant RAS , second-line, stage IV colorectal cancer wild-type RAS, third-line, stage IV colorectal cancer mutant RAS, third-line, stage IV colorectal cancer wild-type RAS, fourth-line, stage IV colorectal cancer mutant RAS, fourth-line.
Emerging therapies: Phase III: 15 drugs; Phase II: 20 drugs; Phase I: 14 drugs.